An Analyst Just Declared Eli Lilly the "Clear Winner" of an American Diabetes Association Conference Focused on Weight-Loss Drugs. Novo's Chief Scientist Disagrees. Who's Right?

Eli Lilly emerged as the standout at the American Diabetes Association conference, according to RBC analyst Trung Huynh, who cited positive trial data for retatrutide and Foundayo as evidence. The call comes amid a stark performance gap: Lilly reported 56% revenue growth last quarter, while Novo Nordisk posted negative adjusted sales growth.

Novo Nordisk's chief science officer Martin Holst Lange pushed back, arguing tolerability and effectiveness against comorbidities will determine the ultimate winner in the weight-loss drug race. The diverging narratives arrive as valuation spreads between the two companies widen significantly.

Lilly's retatrutide and Foundayo data from the conference gave bulls fresh ammunition, though Novo maintains its pipeline can close the gap. The conference served as a critical venue for both companies to showcase their next-generation obesity treatments, with Wall Street analysts parsing every data point for competitive advantages.

The 56% revenue surge at Lilly versus contraction at Novo marks one of the sharpest divergences between the two diabetes giants in recent memory, amplifying pressure on Novo to deliver clinical wins.